In a major development, Sun Pharmaceutical Industries Limited., which includes “Sun Pharma” and their subsidiaries and/or associate companies) announced that they have launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India, says a press release published on their website.
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.
Reducing the financial burden of people
Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”
To be available for patients
The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.
FluGuard® is the registered trade mark of Sun Pharma
Did you subscribe to our daily newsletter?
It’s Free! Click here to Subscribe!
Source: SunPharma
